Dyne Therapeutics, Inc. Research and Development Expense
Dyne Therapeutics, Inc. (DYN) reported Research and Development Expense of $152.17 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-07-29
- Dyne Therapeutics, Inc. research and development expense for the quarter ending 2026-06-30 was $152.17M, a 53.34% increase year-over-year.
- Dyne Therapeutics, Inc. research and development expense for the quarter ending 2026-03-31 was $100.89M, a 5.22% decline year-over-year.
- Dyne Therapeutics, Inc. research and development expense for the quarter ending 2025-12-31 was $95.43M, a 16.66% increase year-over-year.
- Dyne Therapeutics, Inc. research and development expense for the quarter ending 2025-09-30 was $97.22M, a 4.76% increase year-over-year.
- Dyne Therapeutics, Inc. research and development expense for fiscal 2025 was $398.33M, a 41.55% increase from fiscal 2024.
- Dyne Therapeutics, Inc. research and development expense for fiscal 2024 was $281.41M, a 33.52% increase from fiscal 2023.
- Dyne Therapeutics, Inc. research and development expense for fiscal 2023 was $210.76M, a 47.63% increase from fiscal 2022.
- Dyne Therapeutics, Inc. research and development expense for fiscal 2022 was $142.76M, a 17.68% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $152.17M 10-Q · filed 2026-07-29 | $253.18M 10-Q · filed 2026-07-29 | $348.49M derived: sum of 3 quarters · filed 2026-07-29 | $445.71M derived: sum of 4 quarters · filed 2026-07-29 |
| 2026-03-31 | $100.89M 10-Q · filed 2026-05-11 | $196.32M derived: sum of 2 quarters · filed 2026-05-11 | $293.54M derived: sum of 3 quarters · filed 2026-05-11 | $392.77M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-12-31 | $95.43M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $192.65M derived: sum of 2 quarters · filed 2026-03-02 | $291.89M derived: sum of 3 quarters · filed 2026-07-29 | $398.33M 10-K · filed 2026-03-02 |
| 2025-09-30 | $97.22M 10-Q · filed 2025-11-05 | $196.46M derived: sum of 2 quarters · filed 2026-07-29 | $302.90M 10-Q · filed 2025-11-05 | $384.71M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-06-30 | $99.24M 10-Q · filed 2026-07-29 | $205.68M 10-Q · filed 2026-07-29 | $287.49M derived: sum of 3 quarters · filed 2026-07-29 | $380.29M derived: sum of 4 quarters · filed 2026-07-29 |
| 2025-03-31 | $106.45M 10-Q · filed 2026-05-11 | $188.25M derived: sum of 2 quarters · filed 2026-05-11 | $281.05M derived: sum of 3 quarters · filed 2026-05-11 | $343.31M derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $81.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $174.60M derived: sum of 2 quarters · filed 2026-03-02 | $236.87M derived: sum of 3 quarters · filed 2026-03-02 | $281.41M 10-K · filed 2026-03-02 |
| 2024-09-30 | $92.80M 10-Q · filed 2025-11-05 | $155.06M derived: sum of 2 quarters · filed 2025-11-05 | $199.60M 10-Q · filed 2025-11-05 | $258.45M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $62.26M 10-Q · filed 2025-07-28 | $106.80M 10-Q · filed 2025-07-28 | $165.65M derived: sum of 3 quarters · filed 2026-03-02 | $220.90M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $44.54M 10-Q · filed 2025-05-08 | $103.38M derived: sum of 2 quarters · filed 2026-03-02 | $158.63M derived: sum of 3 quarters · filed 2026-03-02 | $217.76M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $58.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $114.09M derived: sum of 2 quarters · filed 2026-03-02 | $173.22M derived: sum of 3 quarters · filed 2026-03-02 | $210.76M 10-K · filed 2026-03-02 |
| 2023-09-30 | $55.25M 10-Q · filed 2024-11-12 | $114.38M derived: sum of 2 quarters · filed 2024-11-12 | $151.92M 10-Q · filed 2024-11-12 | $185.11M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $59.13M 10-Q · filed 2024-08-12 | $96.67M 10-Q · filed 2024-08-12 | $129.86M derived: sum of 3 quarters · filed 2025-02-27 | $164.53M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $37.54M 10-Q · filed 2024-05-02 | $70.73M derived: sum of 2 quarters · filed 2025-02-27 | $105.40M derived: sum of 3 quarters · filed 2025-02-27 | $152.06M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $33.19M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $67.86M derived: sum of 2 quarters · filed 2025-02-27 | $114.52M derived: sum of 3 quarters · filed 2025-02-27 | $142.76M 10-K · filed 2025-02-27 |
| 2022-09-30 | $34.67M 10-Q · filed 2023-10-30 | $81.33M derived: sum of 2 quarters · filed 2023-10-30 | $109.57M 10-Q · filed 2023-10-30 | $151.87M derived: sum of 4 quarters · filed 2023-10-30 |
| 2022-06-30 | $46.66M 10-Q · filed 2023-08-03 | $74.90M 10-Q · filed 2023-08-03 | $117.20M derived: sum of 3 quarters · filed 2023-08-03 | $153.71M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | $28.24M 10-Q · filed 2023-05-11 | $70.54M derived: sum of 2 quarters · filed 2023-05-11 | $107.05M derived: sum of 3 quarters · filed 2023-05-11 | $130.92M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $42.30M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $78.81M derived: sum of 2 quarters · filed 2023-03-02 | $102.68M derived: sum of 3 quarters · filed 2023-03-02 | $121.31M 10-K · filed 2023-03-02 |
| 2021-09-30 | $36.51M 10-Q · filed 2022-11-03 | $60.38M derived: sum of 2 quarters · filed 2022-11-03 | $79.01M 10-Q · filed 2022-11-03 | $101.11M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $23.87M 10-Q · filed 2022-08-04 | $42.50M 10-Q · filed 2022-08-04 | $64.59M derived: sum of 3 quarters · filed 2022-08-04 | $74.27M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $18.63M 10-Q · filed 2022-05-02 | $40.72M derived: sum of 2 quarters · filed 2022-05-02 | $50.40M derived: sum of 3 quarters · filed 2022-05-02 | $57.74M derived: sum of 4 quarters · filed 2022-05-02 |
| 2020-12-31 | $22.10M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $31.78M derived: sum of 2 quarters · filed 2022-03-10 | $39.11M derived: sum of 3 quarters · filed 2022-03-10 | $45.20M 10-K · filed 2022-03-10 |
| 2020-09-30 | $9.68M 10-Q · filed 2021-11-04 | $17.01M derived: sum of 2 quarters · filed 2021-11-04 | $23.10M 10-Q · filed 2021-11-04 | $27.36M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | $7.33M 10-Q · filed 2021-08-05 | $13.42M 10-Q · filed 2021-08-05 | $17.68M derived: sum of 3 quarters · filed 2021-08-05 | $20.66M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $6.09M 10-Q · filed 2021-05-06 | $10.35M derived: sum of 2 quarters · filed 2021-05-06 | $13.33M derived: sum of 3 quarters · filed 2021-05-06 | |
| 2019-12-31 | $4.26M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | $7.24M derived: sum of 2 quarters · filed 2021-03-04 | $11.04M 10-K · filed 2021-03-04 | |
| 2019-09-30 | $2.98M 10-Q · filed 2020-11-05 | $6.78M 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |